- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors
Authors
Keywords
-
Journal
PHARMACOTHERAPY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-12-28
DOI
10.1002/phar.2210
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Avibactam Pharmacokinetic/Pharmacodynamic Targets
- (2018) Wright W. Nichols et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model
- (2018) Jin Wu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects
- (2018) Matthew L. Rizk et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Past and Present Perspectives on β-Lactamases
- (2018) Karen Bush ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance
- (2018) Patrick N. A. Harris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products
- (2017) Carlos A. Rodriguez et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in anIn VitroInfection Model
- (2016) Brian D. VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in anIn VitroInfection Model
- (2016) Anthony M. Nicasio et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae
- (2016) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Boronic Acid Transition State Inhibitors Active against KPC and Other Class A β-Lactamases: Structure-Activity Relationships as a Guide to Inhibitor Design
- (2016) Laura J. Rojas et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- New β-Lactamase Inhibitors in the Clinic
- (2016) Krisztina M. Papp-Wallace et al. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
- The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria
- (2016) C.M. Pillar et al. LETTERS IN APPLIED MICROBIOLOGY
- β-Lactamases: A Focus on Current Challenges
- (2016) Robert A. Bonomo Cold Spring Harbor Perspectives in Medicine
- Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects
- (2015) Eric Wenzler et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection
- (2015) Johanna Berkhout et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens
- (2015) Karen Bush INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam
- (2015) Renu Singh et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens
- (2015) David P. Nicolau et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam ‘enhancer’
- (2015) Akihiro Morinaka et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Molecular Basis of Selective Inhibition and Slow Reversibility of Avibactam against Class D Carbapenemases: A Structure-Guided Study of OXA-24 and OXA-48
- (2014) Sushmita D. Lahiri et al. ACS Chemical Biology
- Post-β-Lactamase-Inhibitor Effect of Tazobactam in Combination with Ceftolozane on Extended-Spectrum-β-Lactamase-Producing Strains
- (2014) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacodynamics of Imipenem in Combination with β-Lactamase Inhibitor MK7655 in a Murine Thigh Model
- (2014) Eleftheria Mavridou et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Relationship between Ceftolozane-Tazobactam Exposure and Selection for Pseudomonas aeruginosa Resistance in a Hollow-Fiber Infection Model
- (2014) Brian D. VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in anIn VitroInfection Model
- (2013) Brian VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane
- (2013) Brian VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Prolonging β-lactam infusion: A review of the rationale and evidence, and guidance for implementation
- (2013) Shawn H. MacVane et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
- (2013) David E. Ehmann et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The ABCD’s of β-lactamase nomenclature
- (2013) Karen Bush JOURNAL OF INFECTION AND CHEMOTHERAPY
- Community-Associated Extended-Spectrum β-Lactamase–Producing Escherichia coli Infection in the United States
- (2012) Yohei Doi et al. CLINICAL INFECTIOUS DISEASES
- Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects
- (2012) G. Chandorkar et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In VivoComparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms
- (2011) Catharine C. Bulik et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14– and CTX-M-15–producing Escherichia coli and Klebsiella pneumoniae
- (2011) Emilia Titelman et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Clinical Characteristics of Bloodstream Infections Due to Ampicillin-Sulbactam-Resistant, Non-Extended- Spectrum-β-Lactamase-ProducingEscherichia coliand the Role of TEM-1 Hyperproduction
- (2010) Rebecca I. Waltner-Toews et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non- -Lactam -Lactamase Inhibitor
- (2010) T. Stachyra et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections
- (2010) R. Nau et al. CLINICAL MICROBIOLOGY REVIEWS
- Penetration of Antibacterials into Bone
- (2009) Cornelia B. Landersdorfer et al. CLINICAL PHARMACOKINETICS
- Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern
- (2008) Johann DD Pitout et al. LANCET INFECTIOUS DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now